Crossmark

ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis

Crossref DOI link: https://doi.org/10.1186/s13046-018-0851-y

Published Online: 2018-08-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ma, Sai

Lu, Chen-Chen

Yang, Li-Yan

Wang, Juan-Juan

Wang, Bo-Shi

Cai, Hong-Qing

Hao, Jia-Jie

Xu, Xin

Cai, Yan

Zhang, Yu http://orcid.org/0000-0003-1375-1594
Wang, Ming-Rong
Funding

Funding for this research was provided by:

CAMS Innovation Fund for Medical Sciences(CIFMS) (2016-I2M-1-001)

National Key Reserach Project (2017YFE0112100)

National Natural Science Foundation of China (81520108023)

Beijing Natural Science Foundation (7151008)
License Information

Text and Data Mining valid from 2018-08-06
More Information

Article History

Received: 29 June 2018

Accepted: 20 July 2018

First Online: 6 August 2018

Ethics approval and consent to participate

: The study protocol was approved by the Ethics Committee of the Institute of National Cancer Center/Cancer Hospital, CAMS & PUMC (NCC2015G-06). All the animal experiments were approved by the Animal Center of the Institute of National Cancer Center/Cancer Hospital, CAMS & PUMC (NCC2015A013).

: Not applicable.

: The authors declare they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.